Could dropping one drug make stem cell transplants safer and simpler?
NCT ID NCT05256537
First seen Dec 15, 2025 · Last updated May 13, 2026 · Updated 19 times
Summary
This study looks at whether it is safe to skip one immune-suppressing drug (MMF) after a stem cell transplant for blood cancers. About 60 adults will receive the standard transplant and then take only two drugs (cyclophosphamide and tacrolimus) instead of the usual three. The goal is to see if the new cells still grow properly and if severe side effects like graft-versus-host disease are kept under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.